Piotr Rieske

Zeligowskiego 7/9 St
Lodz, LD 90752, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy.

Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy.

Journal: Cells

Published: April 30, 2026

The New Wave of Gene and Cell Therapies Across Diseases.

The New Wave of Gene and Cell Therapies Across Diseases.

Journal: Journal of clinical medicine

Published: January 20, 2026

Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence.

Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence.

Journal: Investigational new drugs

Published: October 01, 2025

Regulation of CAR transgene expression to design semiautonomous CAR-T.

Regulation of CAR transgene expression to design semiautonomous CAR-T.

Journal: Molecular therapy. Oncology

Published: August 26, 2024

First molecules to reactivate RASG12V GTPase activity.

First molecules to reactivate RASG12V GTPase activity.

Journal: BMC cancer

Published: May 08, 2024

The complex journey of targeting RAS in oncology.

The complex journey of targeting RAS in oncology.

Journal: BMC cancer

Published: January 03, 2024

Immunohistochemical detection of EGFRvIII in glioblastoma - Anti-EGFRvIII antibody validation for diagnostic and CAR-T purposes.

Immunohistochemical detection of EGFRvIII in glioblastoma - Anti-EGFRvIII antibody validation for diagnostic and CAR-T purposes.

Journal: Biochemical and biophysical research communications

Published: August 04, 2023

The hope, hype and obstacles surrounding cell therapy.

The hope, hype and obstacles surrounding cell therapy.

Journal: Journal of cellular and molecular medicine

Published: April 27, 2023

Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy.

Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy.

Journal: International journal of molecular sciences

Published: November 11, 2022

Proteomic and Transcriptomic Landscapes of Alström and Bardet-Biedl Syndromes.

Proteomic and Transcriptomic Landscapes of Alström and Bardet-Biedl Syndromes.

Journal: Genes

Published: October 30, 2022

Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells-EGFRvIII Appears as a Weak Oncogene.

Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells-EGFRvIII Appears as a Weak Oncogene.

Journal: International journal of molecular sciences

Published: August 19, 2022

Application and Design of Switches Used in CAR.

Application and Design of Switches Used in CAR.

Journal: Cells

Published: May 03, 2022

Showing 1-12 of 43

Last Updated: 09/26/2026